Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Iwasaki K et al. | Pharmacokinetic study of FK 506 in the rat. | 1991 | Transplant. Proc. | pmid:1721268 |
Kay JE et al. | Uptake of FK 506 by lymphocytes and erythrocytes. | 1991 | Transplant. Proc. | pmid:1721269 |
Jain AB et al. | Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721270 |
Abu-Elmagd KM et al. | Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. | 1991 | Transplant. Proc. | pmid:1721271 |
Dumont FJ et al. | Up-regulation of gene expression by FK 506. | 1991 | Transplant. Proc. | pmid:1721300 |
Rao P et al. | Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. | 1991 | Transplant. Proc. | pmid:1721301 |
DiLella AG and Craig RJ | Characterization of the human FKBP-12 gene and related pseudogenes. | 1991 | Transplant. Proc. | pmid:1721302 |
Kar S and Carr B | Gene expression of FK 506-binding protein. | 1991 | Transplant. Proc. | pmid:1721303 |
Connelly PR | Thermodynamics of interaction of FK 506-binding protein and its ligands. | 1991 | Transplant. Proc. | pmid:1721304 |
Borg AJ and Kumagai M | FK 506 and xenogeneic human anti-porcine cellular reactivity. | 1991 | Transplant. Proc. | pmid:1721332 |
Fung J et al. | A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. | 1991 | Transplant. Proc. | pmid:1721333 |
Winkler M et al. | Use of FK 506 for treatment of chronic rejection after liver transplantation. | 1991 | Transplant. Proc. | pmid:1721334 |
D'Alessandro AM et al. | FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. | 1991 | Transplant. Proc. | pmid:1721335 |
Jensen CW et al. | Pediatric renal transplantation under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721364 |
McCauley J et al. | The question of FK 506 nephrotoxicity after liver transplantation. | 1991 | Transplant. Proc. | pmid:1703344 |
Jordan ML et al. | FK 506 conversion of renal allografts failing cyclosporine immunosuppression. | 1991 | Transplant. Proc. | pmid:1721365 |
Alessiani M et al. | Infections in adult liver transplant patients under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1703345 |
Offner G et al. | FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up. | 1991 | Transplant. Proc. | pmid:1721366 |
Imai K et al. | Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. | 1991 | Transplant. Proc. | pmid:1703347 |
Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group. | 1991 | Transplant. Proc. | pmid:1721367 | |
Starzl TE et al. | Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. | 1991 | Transplant. Proc. | pmid:1703351 |
Freise CE et al. | Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. | 1991 | Transplant. Proc. | pmid:1721397 |
Eidelman BH et al. | Neurologic complications of FK 506. | 1991 | Transplant. Proc. | pmid:1721398 |
Heitman J et al. | FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1705713 |
Goebl MG | The peptidyl-prolyl isomerase, FK506-binding protein, is most likely the 12 kd endogenous inhibitor 2 of protein kinase C. | 1991 | Cell | pmid:1706222 |
de Paulis A et al. | FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. | 1991 | J. Immunol. | pmid:1706398 |
Fukuzawa M et al. | Effect of donor-specific transfusion and FK 506 on small intestine allotransplantation. | 1991 | Transplant. Proc. | pmid:1721427 |
Ogasa N et al. | Effect of FK 506 on growth of transplanted newborn rat intestine. | 1991 | Transplant. Proc. | pmid:1721428 |
de Bruin RW et al. | Fulminant graft-versus-host disease after FK 506 treatment in fully allogeneic small bowel transplantation. | 1991 | Transplant. Proc. | pmid:1721429 |
Langrehr JM et al. | FK 506 inhibits nitric oxide production by cells infiltrating sponge matrix allografts. | 1991 | Transplant. Proc. | pmid:1721430 |
Francavilla A et al. | Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK 506. | 1991 | Hepatology | pmid:1712337 |
Aoki H | [FK 506, a new immunosuppressant produced by a Streptomyces]. | 1991 | Nippon Rinsho | pmid:1712403 |
Hultsch T et al. | Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1712484 |
Miyahara H et al. | Comparative studies of the effects of FK506 and cyclosporin A on passively transferred collagen-induced arthritis in rats. | 1991 | Clin. Immunol. Immunopathol. | pmid:1712688 |
McCauley J et al. | FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. | 1991 | Transplant. Proc. | pmid:1721459 |
Carrieri G et al. | Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. | 1991 | Transplant. Proc. | pmid:1721460 |
Deguchi K et al. | Effects of FK 506 on acute experimental allergic encephalomyelitis. | 1991 | Transplant. Proc. | pmid:1721461 |
Bolton C | The ability of myelin basic protein-sensitised leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisolone. | 1991 | Transplant. Proc. | pmid:1721462 |
DeFranco AL | Signal transduction. Immunosuppressants at work. | 1991 | Nature | pmid:1715515 |
Flanagan WM et al. | Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. | 1991 | Nature | pmid:1715516 |
McWhinnie DL and Morris PJ | Combination drug therapies for immunosuppression in transplantation. | 1991 | Ann. Acad. Med. Singap. | pmid:1724724 |
Pourtier-Manzanedo A et al. | FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. | 1991 | Anticancer Drugs | pmid:1724925 |
Unmasking immunosuppression. | 1991 | Lancet | pmid:1717800 | |
Ericzon BG et al. | Effect of FK 506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and nontransplanted animals. | 1991 | Transplant. Proc. | pmid:1703695 |
Markus PM et al. | Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. | 1991 | Transplantation | pmid:1718063 |
Kumano K et al. | FK 506-induced nephrotoxicity in rats. | 1991 | Transplant. Proc. | pmid:1703696 |
Ryu S and Yasunami Y | The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. | 1991 | Transplantation | pmid:1718064 |
Kuroki H et al. | Morphological and immunological analysis of rats with long-term-surviving limb allografts induced by a short course of FK 506 or cyclosporine. | 1991 | Transplant. Proc. | pmid:1703697 |
Starzl TE et al. | Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. | 1991 | Transplantation | pmid:1718068 |
Morris RE et al. | Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. | 1991 | Transplant. Proc. | pmid:1703698 |